The effects of sugammadex on coagulation in pregnant rats

Some studies have reported that sugammadex affects coagulation parameters. However, the effects of sugammadex on coagulation in pregnant women have not been adequately evaluated. This study investigated the effects of sugammadex administration on routine coagulation tests and levels of coagulation factors (FII, FV, FVII, FVIII, FIX, and FX) in pregnant rats. After ethics committee approval (2019/06), 24 female Wistar albino rats (n = 12; 19-20 days of gestation; weight 230-380 g) were randomly divided into four groups: control (n = 6), sugammadex (n = 6), pregnant (n = 6), and pregnant sugammadex (n = 6). Ketamine (50 mg/kg) and xylazine (10 mg/kg) were administered intraperitoneally to all groups. Saline (SF) (1 ml/kg) was administered to the control and pregnant groups. Sugammadex was administered to the sugammadex and pregnant sugammadex groups at a dose of 16 mg/kg. Blood samples were collected at 30 min after SF and sugammadex administration in all rats. The levels of PT, INR, aPTT, fibrinogen and coagulation factors were measured in plasma obtained from blood samples. All animals were sacrificed by cervical dislocation after the procedure. The mean weights of the rats were significantly higher in the pregnant groups (pregnant and pregnant sugammadex groups) than in the non-pregnant groups (control and sugammadex groups). The mean PT and INR values were significantly lower in the pregnant than non-pregnant groups. No significant differences were observed in any of the parameters evaluated between the sugammadex-and SF-administered groups. Sugammadex administration did not affect routine coagulation tests or the levels of coagulation factors in pregnant rats.